PRMEPrime Medicine, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $5M
- 55% YoY
- Operating margin
- -4498.1%
- 34% YoY
- EBITDA
- −$201M
- 2.4% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired632% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3M | $5M | 55% |
| Operating income | −$84M | −$117M | −$205M | −$202M | −$208M | 2.9% |
| Net income | −$165M | −$122M | −$198M | −$196M | −$201M | 2.7% |
| Operating cash flow | −$34M | −$132M | −$165M | −$123M | −$163M | 32% |
| Capex | $4M | $16M | $9M | $7M | $5M | 38% |
| Stock-based comp | $2M | $6M | $14M | $26M | $29M | 12% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.